ADVERTISEMENT
ADVERTISEMENT

drug development, clinical trials

Right-to-Try Bill Passes the Senate
Catherine Offord | Aug 4, 2017 | 2 min read
The legislation removes restrictions for seriously ill patients to access experimental treatments that have not received FDA approval.
Personalized Cancer Vaccines Show Promise for Melanoma
Jef Akst | Jul 6, 2017 | 2 min read
In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 
More Than 1 Percent of Clinical Trial Reports Appear Flawed
Jef Akst | Jun 5, 2017 | 2 min read
A new screening tool flags dozens of papers with potential errors.
Stem Cell Trial Data Mostly Go Unpublished
Anna Azvolinsky | May 5, 2017 | 4 min read
Less than half of completed stem cell studies in humans are published in peer-reviewed journals, according to an analysis of regenerative medicine trials. 
Evaluating Epigenome-Targeting Cancer Therapies
Jef Akst | Apr 3, 2017 | 3 min read
At the annual American Association for Cancer Research meeting, researchers discuss the importance of understanding the epigenetic contributors to cancer progression and treatment response.
Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy
John D. Loike and Jennifer Miller | Feb 1, 2017 | 4 min read
What can be done to lower development costs and drug prices?
Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017 | 7 min read
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.
Infographic: The Cost of Drug Development
John D. Loike and Jennifer Miller | Jan 31, 2017 | 1 min read
Expensive clinical trials and few drug approvals can drive up drug prices for consumers.
Repurposing Existing Drugs for New Indications
Anna Azvolinsky | Jan 1, 2017 | 10+ min read
An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.
Infographic: Repurposing Strategies
Anna Azvolinsky | Dec 31, 2016 | 1 min read
Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.
Opinion: Not All Genetic Databases Are Equal
Charles M. Strom | Dec 1, 2016 | 4 min read
Sorting out which data sets are clinical-grade is key to helping patients.
New Support for Experimental Alzheimer’s Drug
Jef Akst | Nov 2, 2016 | 2 min read
Merck’s verubecestat, which is currently being tested in two Phase 3 studies, is safe, according to newly published Phase 1 data.
Pet Meds Adapted from Human Therapies
Jenny Rood | Oct 1, 2016 | 8 min read
Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.
Feds Demand More Clinical Trial Reporting
Kerry Grens | Sep 19, 2016 | 2 min read
Expanded US Health and Human Services rules will require the results of more human studies to be made public.
The Challenges of Rare-Disease Research
Jyoti Madhusoodanan | Sep 1, 2016 | 8 min read
With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.
Toward Targeted Therapies for Autoimmune Disorders
Lawrence Steinman | Jun 1, 2016 | 10 min read
Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.
Another Fatal-Disease Drug in Limbo
Jef Akst | Apr 26, 2016 | 2 min read
A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.
Cannabis-Based Drug for Epilepsy
Jef Akst | Mar 14, 2016 | 1 min read
A marijuana-derived compound shows continued success in treating children with a rare form of the seizure disorder. 
Desperately Seeking Shut-Eye
Anna Azvolinsky | Mar 1, 2016 | 7 min read
New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.
Clinical Trial Data Underreported: Study
Kerry Grens | Nov 16, 2015 | 1 min read
One-third of the human experiments for approved drugs failed transparency requirements.
ADVERTISEMENT